-
1 month ago | 
mskcc.org | Julie Grisham
It was hard enough for Stephanie Soto-Vega to get the news that her breast cancer had spread to her hip bones and spine. Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried,” remembers Stephanie, who had a new baby named Luna.
-
1 month ago | 
mskcc.org | Julie Grisham
An international phase 3 clinical trial of a new drug combination for treating the blood cancer myelofibrosis found that adding a second, experimental drug to standard treatment was more effective than the standard treatment alone. Further, adding the second drug did not significantly increase side effects. Memorial Sloan Kettering Cancer Center (MSK) enrolled the most patients in the trial.
-
2 months ago | 
mskcc.org | Julie Grisham
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints. Sarcoma oncologist William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), led the international phase 3 MOTION trial that resulted in the drug’s approval.
-
Jan 16, 2025 | 
mskcc.org | Julie Grisham
When Aaron von Freter learned he had chronic myeloid leukemia (CML), he “felt like the room was spinning,” he remembers. “I thought I’d been served a death sentence.”Aaron was 45 years old and had no symptoms. His diagnosis came after standard bloodwork revealed an extremely high white blood cell count.
-
Jan 14, 2025 | 
geneticliteracyproject.org | Julie Grisham
GLP Policy & Performance Review, Fall 2024 The GLP is committed to full transparency. Download the report.
-
Jan 10, 2025 | 
medicalxpress.com | Julie Grisham
Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic mutations found in tumors to match patients with specific precision oncology therapies—many of which have become part of standard treatment. Many more precision oncology treatments are being tested in clinical trials.
-
Jan 8, 2025 | 
mskcc.org | Julie Grisham
Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic mutations found in tumors to match patients with specific precision oncology therapies — many of which have become part of standard treatment. Many more precision oncology treatments are being tested in clinical trials.
-
Dec 4, 2024 | 
mskcc.org | Julie Grisham
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab (Bizengri®) for treating patients with advanced pancreatic canceror non-small cell lung cancer (NSCLC) that has an alteration called an NRG1 gene fusion and whose disease progressed after other treatments.
-
Nov 19, 2024 | 
mskcc.org | Julie Grisham
On November 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to the drug zanidatamab (Ziihera®) to treat advanced and metastatic bile duct cancer (cholangiocarcinoma) and other biliary tract cancers that have high levels of a protein called HER2 and do not respond to chemotherapy. The clinical trial that resulted in the drug’s approval was co-led by gastrointestinal medical oncologist and early drug development specialist James J.
-
Nov 18, 2024 | 
mskcc.org | Julie Grisham
The diagnosis was earth-shattering, especially for someone who had never smoked.. Jhalene Mundin, a 35-year-old mother of two young children, was told in July 2023 that she had stage 4 (metastatic) non-small cell lung cancer. It had spread beyond her lungs and was considered inoperable. At the time, she was a nurse working at another hospital in Manhattan.
